CorVent Medical, Inc.

CorVent Medical, Inc. specializes in developing innovative medical devices aimed at improving patient outcomes and healthcare efficiency. Their focus is on addressing critical care needs with advanced technology solutions. CorVent Medical, Inc.

is a medical technology company focusing on creating solutions for critical care environments. The company was founded by Adam Rosenwach, Mark Gelfand, and Zoar Engelman. Their headquarters is located in New York, US. In May 2020, CorVent raised USD 4.

5 mn in Seed funding led by Sofinnova Partners, with participation from Deerfield Management, Exor Seeds, Genesis Innovation Group, Pagliuca Family Office, and Redmile Group. This funding was crucial in supporting their growth strategy and product development efforts. CorVent Medical offers innovative solutions in the medical technology sector, focusing on enhancing critical care through advanced device offerings. Their flagship products are designed to improve patient management in medical settings, particularly for emergency and intensive care applications.

The company's product suite addresses the challenges faced by healthcare providers, providing enhanced functionalities for monitoring and treating critical patients, thus improving operational efficiencies in healthcare facilities. CorVent Medical generates revenue through a product sales model, primarily supplying hospitals and healthcare providers with their medical devices. The company engages in business-to-business (B2B) contracts, ensuring a reliable revenue stream as healthcare facilities integrate their products into patient care routines. This model is structured around both direct sales and long-term agreements with healthcare institutions.

CorVent Medical is focused on expanding its product offerings, with plans to launch new medical devices designed specifically for critical care by late 2021. The company aims to enter new markets across North America and Europe, targeting hospitals and healthcare networks that require advanced medical technology. The recent Seed funding round of USD 4. 5 mn will be utilized to accelerate product development efforts, enhance research capabilities, and support market entry initiatives.